Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Cohort

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    2,062 result(s) found for: Cohort. Displaying page 1 of 104.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2019-000926-23 Sponsor Protocol Number: B1851178 Start Date*: 2024-03-07
    Sponsor Name:Pfizer, Inc.
    Full Title: A PHASE 3 OPEN-LABEL TRIAL TO ASSESS THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN INFANTS AND YOUNG CHILDREN IN CHINA WHO ARE NAIVE TO PNEUMOCOCCAL V...
    Medical condition: Pneumococcal Infections
    Disease:
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2016-002676-27 Sponsor Protocol Number: MedOPP096-MO39229 Start Date*: 2017-05-25
    Sponsor Name:Medica Scientia Innovation Research (MedSIR)
    Full Title: Chemotherapy-free trastuzumab and pertuzumab in HER2-positive breast cancer: FDG-PET response-adapted strategy. The PHERGain study
    Medical condition: HER2-positive breast cancer
    Disease: Version SOC Term Classification Code Term Level
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065430 HER-2 positive breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) DE (Trial now transitioned) GB (GB - no longer in EU/EEA) BE (Completed) FR (Trial now transitioned) PT (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-005744-34 Sponsor Protocol Number: iCHF-2 Start Date*: 2019-01-03
    Sponsor Name:University Medical Centre Hamburg-Eppendorf
    Full Title: Randomized, Double-Blinded, Controlled Trial of Intravenous Iron in Patients With Cardiovascular Disease and Concomitant Iron Deficiency
    Medical condition: Patients With Cardiovascular Disease and Concomitant Iron Deficiency Cohort A: Acute myocardial infarction (AMI) Cohort B: Paroxysmal atrial fibrillation or persitent atrial fibrillation (AF) Coho...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10071667 Persistent atrial fibrillation LLT
    20.0 10007541 - Cardiac disorders 10034039 Paroxysmal atrial fibrillation LLT
    20.0 10022891 - Investigations 10050527 Ejection fraction PT
    20.0 10007541 - Cardiac disorders 10000891 Acute myocardial infarction PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-020413-90 Sponsor Protocol Number: VX09-809-102 Start Date*: 2011-01-06
    Sponsor Name:Vertex Pharmaceuticals Incorporated
    Full Title: A Phase 2, Multicenter, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Lumacaftor Monotherapy, and L...
    Medical condition: Cystic Fibrosis
    Disease: Version SOC Term Classification Code Term Level
    17.0 10010331 - Congenital, familial and genetic disorders 10011762 Cystic fibrosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) GB (Completed) IE (Completed)
    Trial results: View results
    EudraCT Number: 2020-005114-18 Sponsor Protocol Number: MK-1308A-008 Start Date*: 2021-07-20
    Sponsor Name:Merck Sharp & Dohme LLC
    Full Title: A Phase 2, Multicenter, Multi Arm, Study to Evaluate MK-1308A (Co-formulated quavonlimab (MK-1308)/pembrolizumab) Versus Other Treatments in Participants with Microsatellite Instability-High (MSI-...
    Medical condition: Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10010035 Colorectal cancer stage IV PT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10079619 MSI-high LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) FR (Trial now transitioned) PL (Trial now transitioned) BE (Trial now transitioned) IT (Trial now transitioned) ES (Ongoing) DK (Trial now transitioned) GR (Trial now transitioned) HU (Trial now transitioned) LT (Trial now transitioned) NL (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-003248-34 Sponsor Protocol Number: IMPAACTP1110 Start Date*: 2016-11-02
    Sponsor Name:NIAID and NICHD
    Full Title: A PHASE I TRIAL TO EVALUATE THE SAFETY AND PHARMACOKINETICS OF RALTEGRAVIR IN HIV-1-EXPOSED NEONATES AT HIGH RISK OF ACQUIRING HIV-1 INFECTION
    Medical condition: New born babies at risk of acquiring HIV from their infected mothers.
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10053529 Vertical human immunodeficiency virus transmission LLT
    Population Age: Newborns, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2014-000778-20 Sponsor Protocol Number: NOR-202 Start Date*: 2014-07-04
    Sponsor Name:Takeda Vaccines, Inc.
    Full Title: A Phase II, Randomized, Double-Blind, Dosage, Safety and Immunogenicity Trial of Intramuscular Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine combined with Aluminum Hydroxide adjuvant in...
    Medical condition: Prevention of gastroenteritis caused by norovirus
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10068189 Gastroenteritis norovirus PT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: FI (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2020-002483-31 Sponsor Protocol Number: UZBRU_VHH2_2 Start Date*: 2020-11-30
    Sponsor Name:UZ Brussel
    Full Title: Phase II study to evaluate the clinical potential of 68GaNOTA-Anti-MMR-VHH2 for in vivo imaging of MMR-expressing Macrophages by means of Positron Emission Tomography (PET) in oncological lesions, ...
    Medical condition: C1: malignancies of the head and neck. C2: malignancy with a solid component C3: carotid plaque, planned for (SOC) carotid endarterectomy. C4: biopsy-proven Hodgkin or non-Hodgkin lymphoma. C5: su...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-001551-31 Sponsor Protocol Number: BGB-3111-304 Start Date*: 2017-12-04
    Sponsor Name:BeiGene, Ltd.
    Full Title: An International, Phase 3, Open-label, Randomized Study of BGB-3111 Compared with Bendamustine plus Rituximab in Patients with Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic...
    Medical condition: Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10003946 B-Lymphocytic, CLL (Kiel Classification) LLT
    21.1 100000004864 10041152 Small lymphocytic lymphoma, consistent with CLL (Working Formulation) LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) HU (Prematurely Ended) CZ (Trial now transitioned) SE (Trial now transitioned) ES (Ongoing) BE (Trial now transitioned) AT (Trial now transitioned) FR (Trial now transitioned) PL (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-004476-35 Sponsor Protocol Number: CCFZ533B2201 Start Date*: 2019-08-19
    Sponsor Name:Novartis Pharma AG
    Full Title: A 48-week, 6-arm, randomized, double-blind, placebo-controlled multicenter trial to assess the safety and efficacy of multiple CFZ533 doses administered subcutaneously in two distinct populations o...
    Medical condition: Sjögren syndrome
    Disease: Version SOC Term Classification Code Term Level
    21.0 10028395 - Musculoskeletal and connective tissue disorders 10040767 Sjogren's syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Completed) HU (Completed) GB (GB - no longer in EU/EEA) NL (Completed) GR (Completed) FR (Completed) DE (Completed) SE (Completed) AT (Completed) SI (Completed) IT (Completed) RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2019-001301-24 Sponsor Protocol Number: IIV-407 Start Date*: 2020-03-20
    Sponsor Name:National Institute for Public Health and the Environment (RIVM)
    Full Title: ‘Primary and booster meningococcal vaccination in Dutch elderly: study to investigate the immune response and determine functional antibodies after the tetravalent MenACWY-TT conjugate vaccine in t...
    Medical condition: The tetravelent MenACWY-TT vaccin administered in this study is used to prevent invasive disease caused by Meningococcal serogroup A, C, W and Y.
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-000875-20 Sponsor Protocol Number: C3291028 Start Date*: 2020-05-14
    Sponsor Name:Pfizer Inc.
    Full Title: A Phase 2b, Multi Center, Randomized, Double-Blind, Vehicle-Controlled, Intra-Participant Study, to Evaluate Efficacy and Safety of Two Regimens of Crisaborole Ointment 2% in Japanese Pediatric and...
    Medical condition: Atopic Dermatitis
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2017-004158-40 Sponsor Protocol Number: P170702J Start Date*: 2018-09-11
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title: A Prospective study evaluating the effect of ocrelizumab on brain innate immune Microglial cells Activation in Multiple Sclerosis using PET-MRI with 18F-DPA714
    Medical condition: Patients with Relapsing MS or primary progressive MS
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-003607-22 Sponsor Protocol Number: CCFZ533A2201 Start Date*: 2018-07-13
    Sponsor Name:Novartis Pharma AG
    Full Title: A partially-blinded, active-controlled, multicenter, randomized study evaluating efficacy, safety, tolerability, pharmacokinetic (PK) and pharmacodynamic (PD) of an anti-CD40 monoclonal antibody...
    Medical condition: Renal transplantation
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021428 - Immune system disorders 10023439 Kidney transplant rejection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) NL (Prematurely Ended) NO (Prematurely Ended) FR (Prematurely Ended) GB (GB - no longer in EU/EEA) DE (Prematurely Ended) ES (Prematurely Ended) CZ (Completed) BE (Prematurely Ended) HU (Prematurely Ended) SK (Prematurely Ended) LV (Prematurely Ended) LT (Prematurely Ended) IT (Prematurely Ended) HR (Completed)
    Trial results: View results
    EudraCT Number: 2021-005504-36 Sponsor Protocol Number: ABNCoV2-03 Start Date*: 2022-09-19
    Sponsor Name:Bavarian Nordic A/S
    Full Title: Evaluation of the Immunogenicity, Safety, and Tolerability of a Single Dose of ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2: a Phase 3 Trial in Two Parts—Randomized, Doubl...
    Medical condition: COVID-19 disease
    Disease: Version SOC Term Classification Code Term Level
    23.1 10042613 - Surgical and medical procedures 10084457 COVID-19 immunisation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2020-003120-17 Sponsor Protocol Number: PDY16963 Start Date*: Information not available in EudraCT
    Sponsor Name:Genzyme Corporation
    Full Title: A 3-part study to evaluate the efficacy and safety of venglustat in combination with Cerezyme in adult and pediatric patients with Gaucher disease Type 3 (GD3) with open-label long-term treatment
    Medical condition: Gaucher disease type 3
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10075699 Gaucher's disease type III PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) DE (Prematurely Ended) HU (Prematurely Ended) FR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-002216-14 Sponsor Protocol Number: 1277 Start Date*: 2017-07-26
    Sponsor Name:Clinical Pharmacology, MUV
    Full Title: Investigation of Pharmacokinetic of Antiinfective Therapy in Healthy Subjects and Severely Burned Patients Admitted to the ICU
    Medical condition: This is an exploratory pharmacokinetic trial in healthy volunteers (cohort A) and patients with severe burns admitted to the ICU (cohort B). The Information retrieved by these investigations will h...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-005217-24 Sponsor Protocol Number: GS-US-326-1100 Start Date*: 2015-11-19
    Sponsor Name:Gilead Sciences, Inc
    Full Title: A Combined Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Induction and Maintenance Study Evaluating the Safety and Efficacy of GS-5745 in Subjects with Moderately to Severely Active Ulce...
    Medical condition: Ulcerative Colitis
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004856 10045365 Ulcerative colitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) CZ (Prematurely Ended) SK (Prematurely Ended) BG (Prematurely Ended) GB (Completed) AT (Prematurely Ended) DE (Completed) BE (Completed) NL (Prematurely Ended) LV (Prematurely Ended) SE (Prematurely Ended) ES (Completed) IE (Prematurely Ended) IS (Prematurely Ended) HR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-003338-29 Sponsor Protocol Number: MK-3475-100 Start Date*: 2016-04-20
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase II, Open-label, Single-arm, Multicenter Study to Evaluate Efficacy and Safety of Pembrolizumab Monotherapy in Subjects with Advanced Recurrent Ovarian Cancer
    Medical condition: A:platinum-resistant or partially platinum-sensitive recurrent ovarian cancer (OC) who received 1 but no more than 3 prior lines of anticancer regimens/local standard following primary or interval ...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: SE (Completed) ES (Completed) LT (Completed) DE (Completed) FI (Completed) NO (Completed) BE (Completed) NL (Completed) FR (Completed) PL (Completed) GB (GB - no longer in EU/EEA) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-001346-34 Sponsor Protocol Number: IMM-101-015 Start Date*: 2018-07-27
    Sponsor Name:Immodulon Therapeutics Ltd
    Full Title: A Study of the Safety and Efficacy of IMM-101 in Combination with Checkpoint Inhibitor Therapy in Patients with Advanced Melanoma
    Medical condition: Unresectable, Stage III or Stage IV metastatic melanoma who are either previously untreated (cohort A), or whose disease has progressed during PD-1 blockade (cohort B).
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028980 Neoplasm PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025671 Malignant melanoma stage IV PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025670 Malignant melanoma stage III PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 09 08:27:51 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA